Clinical Trial Update: Identification of Predictive Biomarker of Regorafenib in Refractory Colorectal Cancer [NA]

View source ↗

Summary

The trial update reports a predictive biomarker for regorafenib in refractory metastatic colorectal cancer. This could inform patient selection for regorafenib …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• Regorafenib (regorafenib)
• Stivarga (regorafenib)

Snippet

Sponsor: Seoul National University Hospital | Conditions: Metastatic Colorectal Cancer | NA | Status: COMPLETED